Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy

  title={Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy},
  author={C. Ross and Hagit Katzov-Eckert and M. Dub{\'e} and B. Brooks and S. Rassekh and A. Barhdadi and Yassamin Feroz-Zada and H. Visscher and A. Brown and M. Rieder and P. Rogers and M. Phillips and B. Carleton and M. Hayden},
  journal={Nature Genetics},
  • C. Ross, Hagit Katzov-Eckert, +11 authors M. Hayden
  • Published 2009
  • Biology, Medicine
  • Nature Genetics
  • Cisplatin is a widely used and effective chemotherapeutic agent, although its use is restricted by the high incidence of irreversible ototoxicity associated with it. In children, cisplatin ototoxicity is a serious and pervasive problem, affecting more than 60% of those receiving cisplatin and compromising language and cognitive development. Candidate gene studies have previously reported associations of cisplatin ototoxicity with genetic variants in the genes encoding glutathione S-transferases… CONTINUE READING
    109 Citations
    Economic impact of a genetic test for cisplatin-induced ototoxicity
    • 20
    • PDF
    Chemotherapy refractory testicular germ cell tumor is associated with a variant in Armadillo Repeat gene deleted in Velco-Cardio-Facial syndrome (ARVCF)
    • 12
    • Highly Influenced
    • PDF
    Analysis of genetic and non genetic risk factors for cisplatin ototoxicity in pediatric patients.
    • 19


    Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin
    • 102
    • PDF
    Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development.
    • 360
    • PDF
    Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors.
    • 183
    Ototoxicity From Cisplatin Therapy in Childhood Cancer
    • 113
    Genotypic Approaches to Therapy in Children
    • 28
    • PDF
    Risk factors for ototoxicity due to cisplatin.
    • 86
    Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
    • 642
    • PDF